A chat with Val Romberg
A question and answer session with the recently appointed CEO of Kedrion, Val Romberg: his first impressions of the company, his views on growth potential, and his reflections on Kedrion’s commitment to developing new anti COVID-19 therapies.
Kedrion announces the appointment of a new CEO
Val Romberg from the USA, one of the most esteemed managers in the industry
COVID-19. Kedrion partners with Columbia University Irving MC
Kedrion and Columbia University release video statements
Kedrion supports the World Federation Of Hemophilia Virtual Summit 2020
The company reaffirms its commitment to the patient community during the COVID-19 epidemic
Kedrion-Kamada collaboration, first batch of Covid-19 IG released in Israel
The two companies are now working to expand the Clinical Development Program to the US
Coronavirus, from plasma an anti Covid-19 treatment
In order to tackle the serious health emergency caused by the COVID-19 pandemic, Kedrion ‘s R&D department set to work immediately to develop potential therapies in the shortest possible time. In this respect, our efforts are concentrated on the use of “convalescent plasma” donated by patients who have recovered from the disease. The plasma, rich in anti-virus antibodies, undergoes pathogen
Kedrion Statement on the novel Coronavirus
In accordance with international, national and local authority guidelines, Kedrion has acted immediately in dealing with the epidemiological emergency linked to the spread of the novel Coronavirus, and has taken all necessary measures to safeguard the health and safety of its employees and guarantee the continuation of business activities. Paolo Marcucci, Chairman & CEO has stated:
SIMEST ENTERS KEDRION BIOPHARMA INC. SHARE CAPITAL
Milan, 24th February 2020 – Società Italiana per le Imprese all’Estero – SIMEST S.p.A. (SIMEST) has today become a minority shareholder of Kedrion Biopharma Inc. (Kedrion Biopharma) with a stake of 4.5% by means of payment of a capital increase of Kedrion Biopharma of USD equivalent of Euro 10 million. Kedrion S.p.A. (Kedrion) will hold the
Kedrion Biopharma Announces Completion of Enrollment for CARES10
A Phase 3, Multi-Center Study to Assess a 10% Ig in Adults with Primary Immunodeficiency Disease
Anti-D 50th Anniversary Celebration Held on Nov. 1, 2018:
1st Annual International Meeting for Global Eradication of Rh Disease